Loading
Avalo Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 14 Nov 2024.
Avalo Therapeutics, Inc.: what insiders have been doing
Every trade that managers of Avalo Therapeutics, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. In the past year (18 October 2025 to 18 October 2026), 67 filings came from 14 insiders.
Only sales appear on the open market, 22 sales in all totalling €2.2M, filed by 4 insiders. The amount is not disclosed for 2 filings. At €650k, the sale published on 19 August 2026 by Sullivan Christopher Ryan is the largest of the period (0.089% of market cap).
Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
With 67 filings in twelve months, the company is more active than the median of 22 filings across the 5,458 companies we follow on the same exchange. Since 2021, the database holds 42 purchases and 23 sales by insiders of the company. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 59,000 USD and net income at -78.3 m USD.
Other companies in the same sector with recent insider buying flagged by our signals: Anixa Biosciences Inc and Vivos Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
121
Thresholds
n/a
Buy Volume
€3M
42 ops. · all time
Sell Volume
€4M
23 ops. · all time
Who traded when
BuySaleChristopher Ryan Sullivan11 sales
Mittie Doyle9 sales
Almenoff June Sherie1 buy
Goldman Jonathan1 sale
Jennifer Riley1 sale
Since the insiders bought
- -87.1%Entry US$102.24 · Close at T+365 US$13.20
- -98.9%Entry US$1,300.80 · Close at T+365 US$14.16
- -70.6%Entry US$2,016.00 · Close at T+365 US$592.80
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Avalo Therapeutics, Inc. Strong Buy (bullish), based on 12 analysts. Average price target: US$44.08.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 18,025 of 24,148 companies
34.9
score / 100
Value16
Quality54
FCF yld-8.5%
Earn yld-13%
EV/EBITDA·
ROE-36%
Gross mgn100%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$11.27
Analyst consensus
12 analystsStrong buy
US$30.00Target US$44.08(+291%)US$60.00
Income statement
RevenueUS$59k
Gross profitUS$59k100% margin
EBITDA-US$72.6M-123019% margin
Net income-US$78.3M-132642.4% margin
Valuation
PER (forward)-4.2x
P/Book1.3x
Beta0.70
Balance sheet & cash
Market capUS$604.4M
Total debtUS$392k
Free Cash Flow-US$51.5M
Debt / Equity0%
Profitability & ownership
ROE-36.3%
ROA-18.5%
% insiders1.7%
% institutions133.7%
Last declaration on 18 September 2026
Declarations121 total
12,394 shares@ US$9.880.015% mcap3.6% of flowCommon StockSEC:0001810417-26-000023:0
12,394 shares@ US$16.33350.024% mcap5.9% of flowCommon StockSEC:0001810417-26-000023:1
10,185 shares@ US$8.040.0097% mcap2.4% of flowCommon StockSEC:0001810417-26-000021:0
10,185 shares@ US$17.61970.021% mcap5.2% of flowCommon StockSEC:0001810417-26-000021:1
679 shares@ US$8.040.0006% mcap1.1% of flowCommon StockSEC:0001918845-26-000031:0
679 shares@ US$20.000.0016% mcap2.6% of flowCommon StockSEC:0001918845-26-000031:1
37,945 shares@ US$9.880.044% mcap11.0% of flowCommon StockSEC:0001810417-26-000019:0
2,876 shares@ US$9.880.0034% mcap0.8% of flowCommon StockSEC:0001810417-26-000019:1
37,945 shares@ US$19.85330.089% mcap22.0% of flowCommon StockSEC:0001810417-26-000019:2
3,749 shares@ US$19.94190.0089% mcap2.2% of flowCommon StockSEC:0001810417-26-000019:3
31,031 shares@ US$9.880.036% mcap9.0% of flowCommon StockSEC:0001810417-26-000019:4
31,031 shares@ US$20.05490.074% mcap18.2% of flowCommon StockSEC:0001810417-26-000019:5
1,000 shares@ US$12.650.0015% mcap2.5% of flowCommon StockSEC:0001918845-26-000029:0
1,000 shares@ US$20.000.0024% mcap3.9% of flowCommon StockSEC:0001918845-26-000029:1
31,031 shares@ US$20.05160.074% mcap29.9% of flowCommonSEC144:0001950047-26-008317
3,749 shares@ US$19.94190.0089% mcap3.6% of flowCommonSEC144:0001950047-26-008220
70,709 shares@ US$19.590.16% mcap66.5% of flowCommonSEC144:0001950047-26-008273
5,037 shares@ US$19.590.012% mcap88.8% of flowCommonSEC144:0001950047-26-008276
679 shares@ US$8.040.0006% mcap1.1% of flowCommon StockSEC:0001918845-26-000026:0
679 shares@ US$20.000.0016% mcap2.7% of flowCommon StockSEC:0001918845-26-000026:1
2,655 shares@ US$19.59030.0062% mcap95.2% of flowCommon StockSEC:0002047607-26-000008:0
2,655 shares@ US$19.59030.0062% mcap100.0% of flowCommonSEC144:0001950047-26-007948
679 shares@ US$18.320.0015% mcap11.2% of flowCommonSEC144:0001950047-26-007908
1,000 shares@ US$12.650.0015% mcap2.5% of flowCommon StockSEC:0001918845-26-000024:0
1,000 shares@ US$20.000.0024% mcap4.0% of flowCommon StockSEC:0001918845-26-000024:1
25 of 121 declarations
About Avalo Therapeutics, Inc.
Avalo Therapeutics, Inc. (NASDAQ: AVTX) is a U.S.-listed clinical-stage biopharmaceutical company focused on immune-mediated inflammatory diseases. For French, Belgian, and Swiss investors, Avalo should be viewed as a small-cap biotech with no mature commercial franchise yet, and therefore a company whose investment case is primarily driven by clinical execution, regulatory milestones, and financing capacity rather than near-term sales. The company is headquartered in the United States, in Wayne (Chesterbrook), Pennsylvania. Its current strategy is highly focused: Avalo says it is fully dedicated to therapies targeting the IL-1β pathway, a key inflammatory signaling axis. Its lead asset is abdakibart (AVTX-009), an anti-IL-1β monoclonal antibody currently being evaluated in a Phase 2 trial in hidradenitis suppurativa (HS), a chronic inflammatory skin disease with substantial unmet medical need.
Avalo’s history shows a clear strategic transformation. The business previously operated under the name Cerecor Inc. and adopted the Avalo Therapeutics name in August 2021 to reflect a stronger emphasis on immunology and diseases with significant unmet therapeutic need. Company disclosures also indicate that Avalo completed a merger with Aevi Genomic Medicine in February 2020, which helped reshape the pipeline and the company’s clinical identity. Over the past several years, Avalo has been streamlining its portfolio and concentrating resources on its lead program, a common approach among development-stage biotech companies seeking to maximize the probability of a meaningful clinical readout.
Read moreShow less
Operationally, Avalo does not yet market any approved products. Its business model is based on research, clinical development, and, if successful, regulatory approval followed by eventual commercialization or partnering. The company is also exploring whether abdakibart could be expanded into additional inflammatory indications where unmet need remains high. From a competitive standpoint, Avalo is not positioned as a broad-based pharmaceutical player; rather, it is a focused innovation vehicle competing on scientific differentiation, trial data, and the potential breadth of the IL-1β mechanism. That said, its narrow asset concentration also creates a pronounced binary-risk profile.
Recent developments are material. Avalo reported positive Phase 2 topline data for abdakibart in HS, released its first-quarter 2026 financial results, and announced on May 5, 2026 the pricing of a $375 million public offering. In practical terms, that financing event should strengthen the company’s near-term operating runway and support ongoing clinical development. Overall, AVTX remains a high-risk, catalyst-driven biotech story listed on the NASDAQ in the United States, with valuation likely to remain highly sensitive to future trial outcomes, regulatory progress, and capital-market conditions.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
